Stereotactic ablative radiotherapy for the treatment of oligometastatic cancer: a clinical review as part of a health technology assessment v1.0

Lachance CC, Tran K, Carson E, Kim J, Palma D, Loewen S, Rader T, MacDougall D, Ford C
Record ID 32018002263
English
Original Title: Stereotactic ablative radiotherapy for the treatment of oligometastatic cancer
Authors' objectives: Stereotactic ablative body radiotherapy (SABR) is a newer form of radiation treatment that delivers high doses to specific body sites over a shorter treatment period than conventional radiotherapy. For cancer therapy, including oligometastatic cancer, SABR is a non-invasive alternative to surgical treatment and an option for patients who are medically inoperable. However, there is a need to determine which patients should be treated with SABR to achieve the greatest benefit and how their disease should be managed. To inform decision-making on the expanded use of SABR in Canada, CADTH is undertaking a Health Technology Assessment (HTA). As part of this HTA, a clinical review was completed regarding the effectiveness and safety of SABR, with or without standard care, for the treatment of oligometastatic cancer. This review is being regularly updated according to a living systematic review approach. CADTH is also undertaking an Environmental Scan of implementation considerations that will contribute to this HTA to further support decision-making.
Details
Project Status: Completed
URL for project: https://cadth.ca/stereotactic-ablative-radiotherapy-treatment-oligometastatic-cancer
URL for protocol: https://cadth.ca/sites/default/files/pdf/ht0029-sabr-for-oligometastatic-cancer-clinical-protocol.pdf
Year Published: 2021
URL for published report: https://cadth.ca/sites/default/files/attachments/2021-06/stereotactic_ablative_radiotherapy_for_the_treatment_of_oligometastatic_cancer_v1.pdf
URL for additional information: https://cadth.ca/stereotactic-ablative-radiotherapy-treatment-oligometastatic-cancer
English language abstract: An English language summary is available
Publication Type: Mini HTA
Country: Canada
MeSH Terms
  • Neoplasms
  • Radiosurgery
  • Neoplasm Metastasis
Keywords
  • Stereotactic radiotherapy
  • Cancer
  • Stereotactic ablative body radiotherapy
  • SABR
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: <p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.